## Paraic A Kenny

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4997571/paraic-a-kenny-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56
papers

4,351
citations

26
h-index

65
ext. papers

4,876
ext. citations

26
h-index

5.35
ext. citations

27
L-index

#	Paper	IF	Citations
56	Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2022</b> , 103, 115656	2.9	O
55	Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer. <i>Antibody Therapeutics</i> , <b>2021</b> , 4, 252-261	5.8	1
54	Outbreak or pseudo-outbreak? Integrating SARS-CoV-2 sequencing to validate infection control practices in a dialysis facility. <i>American Journal of Infection Control</i> , <b>2021</b> , 49, 1232-1236	3.8	1
53	Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, e433-e438	3	6
52	Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 179, 653-660	4.4	2
51	Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. <i>Experimental and Molecular Pathology</i> , <b>2019</b> , 110, 104260	4.4	4
50	SAT-331 Elucidating the Role of Breast Cancer Specific GATA3 Mutation in Estrogen Receptor Positive Breast Cancer. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,	0.4	78
49	InferCNV, a python web app for copy number inference from discrete gene-level amplification signals noted in clinical tumor profiling reports. <i>F1000Research</i> , <b>2019</b> , 8, 807	3.6	2
48	InferAMP, a python web app for copy number inference from discrete gene-level amplification signals noted in clinical tumor profiling reports. <i>F1000Research</i> , <b>2019</b> , 8, 807	3.6	3
47	MTORC1/2 Inhibition as a Therapeutic Strategy for Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 346-355	6.1	13
46	Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels. <i>Life Sciences</i> , <b>2018</b> , 198, 128-135	6.8	18
45	Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. <i>Anticancer Research</i> , <b>2018</b> , 38, 4435-4441	2.3	16
44	Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors. <i>Analytical Biochemistry</i> , <b>2018</b> , 551, 26-28	3.1	
43	The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	17
42	Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth. <i>Breast Cancer Research</i> , <b>2018</b> , 20, 131	8.3	6
41	Genomic analysis of melanoma evolution following a 30-year disease-free interval. <i>Journal of Cutaneous Pathology</i> , <b>2017</b> , 44, 805-808	1.7	3
40	Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-6	3.6	3

## (2011-2017)

39	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	9
38	Altered purinergic receptor-Call+ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells. <i>Molecular Oncology</i> , <b>2016</b> , 10, 166-78	7.9	61
37	Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERPositive Breast Cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 4830-8	10.1	27
36	Comparative analysis of GATA3 mutation profiles between Asian and Western patients with breast cancer. Is there really a difference?. <i>Cancer</i> , <b>2014</b> , 120, 2778-9	6.4	
35	PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. <i>Cancer Prevention Research</i> , <b>2014</b> , 7, 407-17	3.2	10
34	Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2013</b> , 434, 695	-700	65
33	TACE-dependent TGFIshedding drives triple-negative breast cancer cell invasion. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2587-95	7.5	25
32	Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer. <i>Glycobiology</i> , <b>2013</b> , 23, 1477-90	5.8	23
31	miR-21 mediates hematopoietic suppression in MDS by activating TGF-🛮 signaling. <i>Blood</i> , <b>2013</b> , 121, 287	<b>′5⊵&amp;</b> 1	108
30	Translating Genomic Research into Clinical Practice: Promise and Pitfalls. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 33, 15-2.	3 <sup>7.1</sup>	6
29	Normal range of serum Amphiregulin in healthy adult human females. <i>Clinical Biochemistry</i> , <b>2012</b> , 45, 460-3	3.5	10
28	Clarification of the C-terminal proteolytic processing site of human Amphiregulin. <i>FEBS Letters</i> , <b>2012</b> , 586, 3500-2	3.8	6
27	Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2158-68	6.1	88
26	GRB7 is required for triple-negative breast cancer cell invasion and survival. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 607-15	4.4	40
25	Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 28598-608	5.4	53
24	FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3211-20	15.9	87
23	Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. <i>Biochemical and Biophysical Research Communications</i> , <b>2011</b> , 411, 107-10	3.4	26
22	ORAI1-mediated calcium influx in lactation and in breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 448-60	6.1	160

21	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7194-2	0 <sup>1</sup> 3 <sup>2.9</sup>	18
20	Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e23464	3.7	46
19	Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. Journal of Biological Chemistry, <b>2010</b> , 285, 37458-66	5.4	65
18	Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. <i>PLoS Computational Biology</i> , <b>2010</b> , 6, e1000684	5	67
17	Store-independent activation of Orai1 by SPCA2 in mammary tumors. <i>Cell</i> , <b>2010</b> , 143, 84-98	56.2	213
16	Endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity. <i>Cancer Research</i> , <b>2009</b> , 69, 6721-9	10.1	36
15	Localization of plasma membrane and secretory calcium pumps in the mammary gland. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 369, 977-81	3.4	67
14	Targeting the tumor microenvironment. Frontiers in Bioscience - Landmark, 2007, 12, 3468-74	2.8	158
13	Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?. <i>Journal of Cellular Biochemistry</i> , <b>2007</b> , 101, 830-9	4.7	271
12	Three-dimensional culture models of normal and malignant breast epithelial cells. <i>Nature Methods</i> , <b>2007</b> , 4, 359-65	21.6	971
11	TACE: a new target in epidermal growth factor receptor dependent tumors. <i>Differentiation</i> , <b>2007</b> , 75, 800-8	3.5	55
10	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2007</b> , 11, 1287-98	6.4	23
9	The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. <i>Molecular Oncology</i> , <b>2007</b> , 1, 84-96	7.9	715
8	Targeting TACE-dependent EGFR ligand shedding in breast cancer. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 337-45	15.9	203
7	Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 7095-102	10.1	102
6	Tumor reversion: correction of malignant behavior by microenvironmental cues. <i>International Journal of Cancer</i> , <b>2003</b> , 107, 688-95	7.5	282
5	Molecular evolution of immunoglobulin and fibronectin domains in titin and related muscle proteins. <i>Gene</i> , <b>1999</b> , 232, 11-23	3.8	54
4	Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient		3

## LIST OF PUBLICATIONS

3	Interregional SARS-CoV-2 spread from a single introduction outbreak in a meat-packing plant in northeast Iowa	9
2	SARS-CoV-2 sequencing reveals rapid transmission from college student clusters resulting in morbidity and deaths in vulnerable populations	11
1	Outbreak or pseudo-outbreak? Integrating SARS-CoV-2 sequencing to validate infection control practices in an end stage renal disease facility	2